Precision for Value’s Jeremy Schafer discusses the concept of indication-based drug contracting and how it could represent a new frontier of manufacturer-payer agreements.
Precision’s Chief Scientific Officer Amitabh Chandra and PHE founding partner Dana Goldman address health care’s Short-Termism problem in their latest article for the Harvard Business Review.
Tomas Philipson’s latest Forbes.com Op-Ed examines how international linkages between health care economies will affect how long you and your kids will live.
The Network for Excellence in Health Innovation (NEHI) held a special forum on August 19th, focusing on better use of medicines in diabetes, featuring the recent study and ADA presentation by Precision’s Joanna MacEwan. She discussed her recent work and fielded questions from the NEHI membership– exploring the implications of new research on the use of diabetes medications and what it means for health care delivery reform, insurance benefit design, changes in health care payment and other critical policy issues.
Tomas Philipson’s latest Forbes.com Op-Ed examines end of life care, and why health care is so valuable in the face of death.
Precision’s Tomas Philipson’s latest Forbes.com Op-Ed examines California’s recently enacted vaccination mandate, and the application of economic epidemiology.
NEW YORK, July 8, 2015 – Precision for Value (www.precisionforvalue.com), a Precision for Medicine Company which provides health economics, analytics, and marketing communications services to life sciences clients, today announced the further expansion of its Health Economics and Outcomes Research (HEOR) team to meet growing customer demand. Christopher Blanchette, PhD, was appointed Vice President, Health Economics.
Precision’s Dana Goldman has been elected to ISPOR’s Board of Directors, effective July 1st, 2015. The Board of Directors are elected by ISPOR members – over 9,500 global members were given the opportunity to vote for nominated candidates.
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is the world’s largest professional organization focused on pharmacoeconomics and outcomes research. Its total membership exceeds 16,500 from 120 countries worldwide.
Analysis from Medicare claims data from Precision’s Research Economist Joanna MacEwan, PhD at the American Diabetes Association 2015 Scientific Sessions.
By Miriam E. Tucker
BOSTON — Among US Medicare beneficiaries with type 2 diabetes, out-of-pocket expenses diminish adherence to medication and may end up increasing overall healthcare costs in the long run, a new study finds.
Precision’s Dana Goldman and Senior Research Economist Karen Van Nuys, along with co-authors Victor J Dzau, Geoffrey S Ginsburg and David Agus, address new developments in personalized medicine.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
